Phase II Trial of Capecitabine and Weekly Docetaxel in Metastatic Renal Cell Carcinoma

Shanthi Marur, James Eliason, Lance K. Heilbrun, Brenda Dickow, Daryn W. Smith, Karen Baranowski, Samir Alhasan, Ulka Vaishampayan

Research output: Contribution to journalArticle

Abstract

Objectives: To evaluate the toxicity and efficacy of capecitabine and weekly docetaxel in a phase II clinical trial. Methods: Eligibility included metastatic renal cancer with a maximum of 2 prior regimens, performance status of 0-2, and adequate renal, hepatic, and bone marrow function. Docetaxel was administered intravenously at a dose of 36 mg/m2 weekly on days 1, 8, and 15 of a 28- day cycle and capecitabine was administered orally at a dose of 1800 mg/m2 from days 5-18. Toxicity was assessed on days 1, 8, and 15 of each cycle, and response was evaluated every 2 cycles. Results: Twenty-five patients, 19 white and 6 African American, were enrolled on this phase II trial. The median age was 60 years (range: 39-75 years). Eighteen patients had clear cell histology, 7 had papillary, sarcomatoid, or chromophobe histology. Thirteen had liver/bone metastases and 13 had ≥2 of the Memorial Sloan-Kettering Cancer Center prognostic risk factors. Twelve patients received prior immunotherapy. A total of 93 cycles were administered; median of 3 cycles and range from 0-10 cycles. The therapy was well tolerated. No treatment-related mortality was observed and 2 treatment-related hospitalizations for nausea, diarrhea, and dehydration occurred. Ten patients had stable disease. The median time to progression was 1.7 months and median survival was 11.1 months. Conclusions: The combination of capecitabine and docetaxel was well tolerated in metastatic renal cancer. Clinical activity was predominantly noted in non-clear cell histology in which chemotherapy would be worthy of future investigation.

Original languageEnglish (US)
Pages (from-to)898-902
Number of pages5
JournalUrology
Volume72
Issue number4
DOIs
StatePublished - Oct 2008
Externally publishedYes

Fingerprint

docetaxel
Renal Cell Carcinoma
Histology
Kidney Neoplasms
Phase II Clinical Trials
Liver
Dehydration
African Americans
Immunotherapy
Nausea
Diarrhea
Hospitalization
Therapeutics
Bone Marrow
Neoplasm Metastasis
Kidney
Bone and Bones
Drug Therapy
Survival
Mortality

ASJC Scopus subject areas

  • Urology

Cite this

Marur, S., Eliason, J., Heilbrun, L. K., Dickow, B., Smith, D. W., Baranowski, K., ... Vaishampayan, U. (2008). Phase II Trial of Capecitabine and Weekly Docetaxel in Metastatic Renal Cell Carcinoma. Urology, 72(4), 898-902. https://doi.org/10.1016/j.urology.2008.05.032

Phase II Trial of Capecitabine and Weekly Docetaxel in Metastatic Renal Cell Carcinoma. / Marur, Shanthi; Eliason, James; Heilbrun, Lance K.; Dickow, Brenda; Smith, Daryn W.; Baranowski, Karen; Alhasan, Samir; Vaishampayan, Ulka.

In: Urology, Vol. 72, No. 4, 10.2008, p. 898-902.

Research output: Contribution to journalArticle

Marur, S, Eliason, J, Heilbrun, LK, Dickow, B, Smith, DW, Baranowski, K, Alhasan, S & Vaishampayan, U 2008, 'Phase II Trial of Capecitabine and Weekly Docetaxel in Metastatic Renal Cell Carcinoma', Urology, vol. 72, no. 4, pp. 898-902. https://doi.org/10.1016/j.urology.2008.05.032
Marur S, Eliason J, Heilbrun LK, Dickow B, Smith DW, Baranowski K et al. Phase II Trial of Capecitabine and Weekly Docetaxel in Metastatic Renal Cell Carcinoma. Urology. 2008 Oct;72(4):898-902. https://doi.org/10.1016/j.urology.2008.05.032
Marur, Shanthi ; Eliason, James ; Heilbrun, Lance K. ; Dickow, Brenda ; Smith, Daryn W. ; Baranowski, Karen ; Alhasan, Samir ; Vaishampayan, Ulka. / Phase II Trial of Capecitabine and Weekly Docetaxel in Metastatic Renal Cell Carcinoma. In: Urology. 2008 ; Vol. 72, No. 4. pp. 898-902.
@article{bf4818b0d3b84b6e93d0c37a8b02908e,
title = "Phase II Trial of Capecitabine and Weekly Docetaxel in Metastatic Renal Cell Carcinoma",
abstract = "Objectives: To evaluate the toxicity and efficacy of capecitabine and weekly docetaxel in a phase II clinical trial. Methods: Eligibility included metastatic renal cancer with a maximum of 2 prior regimens, performance status of 0-2, and adequate renal, hepatic, and bone marrow function. Docetaxel was administered intravenously at a dose of 36 mg/m2 weekly on days 1, 8, and 15 of a 28- day cycle and capecitabine was administered orally at a dose of 1800 mg/m2 from days 5-18. Toxicity was assessed on days 1, 8, and 15 of each cycle, and response was evaluated every 2 cycles. Results: Twenty-five patients, 19 white and 6 African American, were enrolled on this phase II trial. The median age was 60 years (range: 39-75 years). Eighteen patients had clear cell histology, 7 had papillary, sarcomatoid, or chromophobe histology. Thirteen had liver/bone metastases and 13 had ≥2 of the Memorial Sloan-Kettering Cancer Center prognostic risk factors. Twelve patients received prior immunotherapy. A total of 93 cycles were administered; median of 3 cycles and range from 0-10 cycles. The therapy was well tolerated. No treatment-related mortality was observed and 2 treatment-related hospitalizations for nausea, diarrhea, and dehydration occurred. Ten patients had stable disease. The median time to progression was 1.7 months and median survival was 11.1 months. Conclusions: The combination of capecitabine and docetaxel was well tolerated in metastatic renal cancer. Clinical activity was predominantly noted in non-clear cell histology in which chemotherapy would be worthy of future investigation.",
author = "Shanthi Marur and James Eliason and Heilbrun, {Lance K.} and Brenda Dickow and Smith, {Daryn W.} and Karen Baranowski and Samir Alhasan and Ulka Vaishampayan",
year = "2008",
month = "10",
doi = "10.1016/j.urology.2008.05.032",
language = "English (US)",
volume = "72",
pages = "898--902",
journal = "Urology",
issn = "0090-4295",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Phase II Trial of Capecitabine and Weekly Docetaxel in Metastatic Renal Cell Carcinoma

AU - Marur, Shanthi

AU - Eliason, James

AU - Heilbrun, Lance K.

AU - Dickow, Brenda

AU - Smith, Daryn W.

AU - Baranowski, Karen

AU - Alhasan, Samir

AU - Vaishampayan, Ulka

PY - 2008/10

Y1 - 2008/10

N2 - Objectives: To evaluate the toxicity and efficacy of capecitabine and weekly docetaxel in a phase II clinical trial. Methods: Eligibility included metastatic renal cancer with a maximum of 2 prior regimens, performance status of 0-2, and adequate renal, hepatic, and bone marrow function. Docetaxel was administered intravenously at a dose of 36 mg/m2 weekly on days 1, 8, and 15 of a 28- day cycle and capecitabine was administered orally at a dose of 1800 mg/m2 from days 5-18. Toxicity was assessed on days 1, 8, and 15 of each cycle, and response was evaluated every 2 cycles. Results: Twenty-five patients, 19 white and 6 African American, were enrolled on this phase II trial. The median age was 60 years (range: 39-75 years). Eighteen patients had clear cell histology, 7 had papillary, sarcomatoid, or chromophobe histology. Thirteen had liver/bone metastases and 13 had ≥2 of the Memorial Sloan-Kettering Cancer Center prognostic risk factors. Twelve patients received prior immunotherapy. A total of 93 cycles were administered; median of 3 cycles and range from 0-10 cycles. The therapy was well tolerated. No treatment-related mortality was observed and 2 treatment-related hospitalizations for nausea, diarrhea, and dehydration occurred. Ten patients had stable disease. The median time to progression was 1.7 months and median survival was 11.1 months. Conclusions: The combination of capecitabine and docetaxel was well tolerated in metastatic renal cancer. Clinical activity was predominantly noted in non-clear cell histology in which chemotherapy would be worthy of future investigation.

AB - Objectives: To evaluate the toxicity and efficacy of capecitabine and weekly docetaxel in a phase II clinical trial. Methods: Eligibility included metastatic renal cancer with a maximum of 2 prior regimens, performance status of 0-2, and adequate renal, hepatic, and bone marrow function. Docetaxel was administered intravenously at a dose of 36 mg/m2 weekly on days 1, 8, and 15 of a 28- day cycle and capecitabine was administered orally at a dose of 1800 mg/m2 from days 5-18. Toxicity was assessed on days 1, 8, and 15 of each cycle, and response was evaluated every 2 cycles. Results: Twenty-five patients, 19 white and 6 African American, were enrolled on this phase II trial. The median age was 60 years (range: 39-75 years). Eighteen patients had clear cell histology, 7 had papillary, sarcomatoid, or chromophobe histology. Thirteen had liver/bone metastases and 13 had ≥2 of the Memorial Sloan-Kettering Cancer Center prognostic risk factors. Twelve patients received prior immunotherapy. A total of 93 cycles were administered; median of 3 cycles and range from 0-10 cycles. The therapy was well tolerated. No treatment-related mortality was observed and 2 treatment-related hospitalizations for nausea, diarrhea, and dehydration occurred. Ten patients had stable disease. The median time to progression was 1.7 months and median survival was 11.1 months. Conclusions: The combination of capecitabine and docetaxel was well tolerated in metastatic renal cancer. Clinical activity was predominantly noted in non-clear cell histology in which chemotherapy would be worthy of future investigation.

UR - http://www.scopus.com/inward/record.url?scp=52949146731&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=52949146731&partnerID=8YFLogxK

U2 - 10.1016/j.urology.2008.05.032

DO - 10.1016/j.urology.2008.05.032

M3 - Article

C2 - 18692873

AN - SCOPUS:52949146731

VL - 72

SP - 898

EP - 902

JO - Urology

JF - Urology

SN - 0090-4295

IS - 4

ER -